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Background: Current Danish treatment algorithms for pharmacological treatment of neuro-
pathic pain (NeP) are tricyclic antidepressants (TCA), gabapentin and pregabalin as first-line 
treatment for the most common NeP conditions. Many patients have insufficient pain relief 
on monotherapy, but combination therapy had not been included in guidelines until recently. 
Based on clinical empiricism and scientific evidence, a Delphi consensus process provided a 
consolidated guidance on pharmacological combination treatment of NeP.
Methods: A two-round virtual internet-based Delphi process with 6 Danish pain specialists was 
undertaken. In the first round, questions were answered individually and anonymously, whereas in 
the second round, the panel openly discussed first round’s summary of outcomes. Combinations of 
pharmacological pain treatments, that is, pregabalin/gabapentin, TCAs, serotonin-norepinephrine 
reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors, opioids, other antiepileptics 
and cutaneous patches, were assessed based on both scientific and clinical practice experiences. The 
Centers for Disease Control and Prevention (CDC) grading system was used for evidence rating.
Results: Combination of pregabalin/gabapentin with TCA is useful in patients who do not gain 
sufficient pain relief or tolerate either drug in high doses, or to improve sleep disturbance. Also, 
combination of pregabalin/gabapentin and SNRIs is reasonably well documented and experi-
enced by some experts to result in sufficient pain relief and fewer side effects than monotherapy. 
Good evidence on efficacy was found for the combination of pregabalin/gabapentin or TCAs 
and opioids, which was also frequently used in clinical practice. The evidence for combining 
TCAs and SNRIs is insufficient, although sometimes used in clinical practice despite the risk 
of serotonin syndrome. For localized NeP, combination therapy with cutaneous patches should 
be considered. There was insufficient scientific evidence for any pharmacologic combination 
therapies with selective serotonin reuptake inhibitors – as well as for other potential combinations.
Conclusions: The study revealed that combination therapy is widely used in clinical practice 
and supported by some scientific evidence. However, further studies are needed.
Keywords: neuropathic pain, combination therapy, Delphi panel, recommendations, CDC 
grading system, clinical practice
Background
Neuropathic pain (NeP) is triggered by a lesion or a disease affecting the somatosensory 
nervous system that alters its structure and function, so that pain occurs spontane-
ously and responses to noxious and innocuous stimuli are pathologically amplified.1 
Peripheral causes of NeP are for example, polyneuropathy, postherpetic neuralgia, 
postoperative pain, and posttraumatic neuralgia, while causes of central NeP are 
spinal cord injuries, stroke, and so on. The current Danish treatment algorithms2–5 are 
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founded on the evidence-based recommendations provided 
by the international pain societies. The European guidelines 
for the pharmacological treatment of NeP issued by the 
European Federation of Neurological Societies recommend 
tricyclic antidepressants (TCA), gabapentin, and pregabalin 
as first-line treatment for the most common NeP conditions, 
including diabetic neuropathy where serotonin-noradrenaline 
reuptake inhibitors (SNRI) are also recommended.6 Finnerup 
et al, recently revised the worldwide applied NeP pharmaco-
therapy recommendations from the Special Interest Group on 
neuropathic pain concluding that there was a strong Grades of 
Recommendation Assessment, Development and Evaluation 
(GRADE) recommendation for use and proposal as first-line 
treatment for TCA, SNRI, pregabalin, and gabapentin.7
Combination therapy, that is, the combination of dif-
ferent pharmacological treatments, has not been a part of 
guidelines until recently. The combination of pregabalin or 
gabapentin with either TCAs or SNRIs is now mentioned 
as a treatment option if a patient cannot tolerate high-dose 
monotherapy.7 The idea of combination therapy using two 
drugs with different mechanisms of action is of great interest, 
as it is widely acknowledged that many patients have insuf-
ficient pain relief on monotherapy with the currently used 
drugs. Furthermore, the drugs used for treatment of NeP have 
severe dose-dependent side effects and tolerability issues, that 
often lead to discontinuation of high-dose monotherapies. 
Other fields of medicine apply combination therapy so as 
to avoid high-dose monotherapy such as for example, treat-
ment of hypertension or diabetes. In a similar fashion, pain 
medicine could benefit from using lower dose combination 
therapies with different mechanisms of action. An example 
could be a moderate dose of a drug reducing calcium influx 
(pregabalin or gabapentin) combined with a moderate dose 
of a drug inhibiting the serotonin and noradrenaline reuptake 
(duloxetine).
In clinical practice, patients with NeP are apparently 
often treated with combination therapy. Furthermore, in the 
literature, some evidence exists on the use of different combi-
nations of pharmacological therapies. Based on this existing 
clinical empiricism, daily clinical practice, and the available 
scientific evidence in the literature on pharmacological 
combination therapy for NeP, a Delphi consensus process 
with 6 Danish pain specialists was established. The Delphi 
process was chosen because it has a structured approach that 
aggregates diverse opinions from experts having knowledge 
within the area of interest that is required for decision making. 
Participants were anonymous during the process. This pre-
vented the authority or personality of some participants from 
dominating others in the process, and allowed free expression 
of opinions. Hence, it is a comprehensive approach when 
aiming at consensus within a specific area of expertise. The 
purpose of the Delphi panel and process was to provide a 
consolidated guidance on pharmacological combination 
treatment of NeP, based on the assessment of the quality of 
existing clinical data and clinical empiricism.
The present article summarizes the Delphi method and 
the recommendations put forward by the 6 Danish Delphi 
panelists with respect to combination therapy for the man-
agement of NeP.
Methods
Based on the available scientific evidence and daily clinical 
experience, the Delphi panel, consisting of six Danish pain 
specialists, discussed the optimal pharmacological combi-
nations for NeP management. This discussion followed the 
methods of a 2-round Delphi process, as this method was 
deemed best suited for reaching consensus. The process was 
run virtually, that is, solely conducted via the internet with 
no physical meeting between the participants, but constant 
virtual access to all documents. The method allowed free and 
anonymous speech without interruptions and submission of 
responses at the convenience of the participants, as well as 
the ability to see and comment upon the other participants’ 
answers. The participation in the study was based on informed 
consent from each of the 6 pain specialists, who also signed 
a contract with Pfizer PFE regarding the complete Delphi 
process. In Denmark, there are no requirements for approval 
by authorities for this type of study. In the first round, each 
member of the Delphi panel answered all questions individu-
ally and anonymously. After the first round, Pfizer compiled 
the ratings, and the participants received a summary of the 
outcome of the first round before attending the second round. 
This allowed the participants to review their own answers 
and comments relative to those of the other participants 
before reviewing all possible combinations again in the 
second round. In this round, the participants only needed 
to answer the questions to which they had further input. A 
final summary report was made after the second round of 
the Delphi process.
Basically, the Delphi panel had to answer 2 overall 
 questions (and some associated sub-questions) regarding 
pharmacological combination pain treatment of NeP:
1. Could the following combination treatments be con-
sidered for treatment of NeP and in what doses and 
regimens?
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2. For which diagnosis should combination treatments be 
considered and how?
a. Peripheral NeP (i.e., polyneuropathies, postoperative 
pain, posttraumatic neuralgia, postherpetic neuralgia)
b. Central NeP (i.e., stroke, spinal cord injuries) should 
combination treatments be considered and how?
Although peripheral as well as central NeP were in scope, 
it should be noted that evidence is almost exclusively within 
peripheral NeP conditions. However, findings in peripheral 
NeP are generally considered also to be applicable for cen-
tral NeP.
The potential pharmacological pain treatments that the 
Delphi panel had to assess in terms of combination therapy 
were: pregabalin/gabapentin, TCAs, SNRIs, selective sero-
tonin reuptake inhibitors (SSRIs), opioids, other antiepilep-
tics and cutaneous patches.
For each of these combined pharmaceutical pain treat-
ment options; all combinations with the other pharmaceutical 
pain therapies were considered and the quality of evidence 
and strength of recommendation of the specific combination 
was rated. Where no or limited scientific evidence was avail-
able, the experts discussed the combination therapy from their 
clinical experiences. For each of the combination therapies, 
the level of evidence is given.
Most of the included literature was provided to the expert 
panel 2 weeks before the Delphi process began. However, 
literature could be added during the process at the will of 
any of the experts. The literature provided upfront was a 
result of comprehensive literature searches in EMBASE and 
MEDLINE using the search terms; combination therapy, 
combination treatment, NeP for both central and peripheral 
neuropathic pain. Only literature in Danish or English was 
included. In order to have a more acceptable number of 
articles for the process, the comprehensive Cochrane review 
on combination therapy from 20128 was included and relevant 
clinical studies published after 2012 was found and included.
The rating of the evidence is based upon the Centers 
for Disease Control and Prevention (CDC) grading system 
presented below in Table 1. The CDC grading system is 
developed by the Infectious Diseases Society of America – 
US Public Health Service and chosen because this evidence 
grading system is a relatively simple and well-suited system 
for ranking recommendations in clinical guidelines.9 Also, 
in the absence of sufficient evidence to build a clear conclu-
sion, final recommendations are based on the majority of 
panel experts’ opinion. Because of the sparse literature on 
combination therapy, it was not possible to apply the more 
comprehensive GRADE system.
A combination of two types of pain pharmacotherapy 
with a rating of “I+A” in this system has the highest rating, 
as it indicates that there is at least one or more properly ran-
domized controlled trial (RCT) as well as strong evidence 
for efficacy and substantial clinical benefit. In this case, the 
combination therapy would be highly recommended. On the 
other hand, a rating of “III+E” implies there is strong evidence 
against the combination therapy being efficacious or that it 
results in adverse outcomes, based on expert opinions only 
(no clinical trials). Such a pharmacologic combination would 
never be recommended.
Results
Following the two rounds in the Delphi panel and process, 
all potential combinations of each of the pharmacological 
NeP treatment therapies were assessed, discussed from a 
Table 1 Centers for Disease Control and Prevention grading system on quality of evidence and strength of recommendation
Quality of evidence Strength of recommendation
Evidence from ≥1 properly randomized controlled trial Strong evidence for efficacy and substantial clinical benefit; strongly 
recommended/good evidence to support a recommendation for or against 
use
Evidence from ≥1 well designed clinical trial, without randomization: 
from cohort or case–control analytic studies (preferable from >1 
center); from multiple time-series studies; or from dramatic results 
from uncontrolled experiments
Strong or moderate evidence for efficacy, but only limited clinical benefit; 
generally recommended/moderate evidence to support a recommendation 
for or against use
Evidence from opinions of respected authorities, based on clinical 
experience, descriptive studies or reports of expert committees 
Insufficient evidence for efficacy; or efficacy does not outweigh possible 
adverse consequences (e.g., drug toxicity or interactions) or cost of 
chemoprophylaxis or alternative approaches; optional/poor evidence to 
support a recommendation
Moderate evidence against efficacy or for adverse outcome; generally not 
recommended
Strong evidence against efficacy or of adverse outcome; never 
recommended
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mechanistic point of view and rated. The ratings and the 
recommendations for each of the potential combination 
therapies are discussed below.
Combination therapy with pregabalin/
gabapentin
Table 2 presents the Delphi panel’s rating of the available 
scientific and clinical evidence for combination therapy with 
pregabalin/gabapentin.
The combination of pregabalin/gabapentin with TCA is 
useful in patients who do not tolerate either drug in high doses 
or who have insufficient pain relief on monotherapy. Gilron 
et al10 (2400 mg gabapentin plus 50 mg TCA) and Holbech 
et al11 (300 mg pregabalin plus 75 mg TCA) studied this 
combination in RCTs in patients with peripheral NeP. Both 
studies showed a significant effect of the combination therapy 
over monotherapy. This combination is also useful to improve 
sleep disturbance due to the sedative effect from TCA.
The Delphi panel assessed the combination of pregabalin/
gabapentin and SNRIs as being reasonably well documented 
(CDC rating I/II + B/C). A study by Tesfaye et al, found no 
significant effect of the moderate-dose combination (300 mg 
pregabalin plus 60 mg duloxetine) therapy on peripheral NeP 
compared with high-dose monotherapy (600 mg pregabalin 
or 120 mg duloxetine).12 However, this combination therapy 
was considered to be potentially effective, safe, and well 
tolerated and if the study had been designed as combination 
vs. identical doses of monotherapy, one could assume that 
the combined effect would have been significantly higher.
Furthermore, adverse event frequencies were generally 
lower during combination therapy. The study by Tanenberg 
et al13 studied a (≥900 mg gabapentin plus 60 mg duloxetine) 
combination and found that insomnia was more frequent 
with duloxetine than duloxetine plus gabapentin and nausea, 
hyperhidrosis, decreased appetite, and vomiting more fre-
quent with duloxetine plus gabapentin than with pregabalin 
(300 mg). There was significant difference in pain relief on 
duloxetine plus gabapentin vs duloxetine or pregabalin mono-
therapies. In parallel, some of the experts concluded that in 
their clinical experience, moderate-dose pregabalin/gabapen-
tin and SNRI combination therapy results in sufficient pain 
relief and fewer side effects compared with monotherapy.
There was insufficient evidence to support a recom-
mendation for the combination of pregabalin/gabapentin 
and SSRIs (CDC rating III + C) (Table 2). SSRIs have at 
best moderate effect (e.g., Sindrup et al14 and Otto et al15), 
but there are also negative trials. All trials are for peripheral 
NeP. Because of poor efficacy, SSRIs are not relevant in the 
treatment of NeP, except for patients already on SSRI for 
other diagnoses like depression or anxiety, in which case 
pregabalin or gabapentin may be added.
Good evidence on efficacy was found for the combina-
tion of pregabalin/gabapentin and opioids in RCTs by Gilron 
et al16 (2400 mg gabapentin plus 60 mg morphine), Hanna 
et al17 (flexible moderate-dose gabapentin plus flexible 
moderate-dose oxycodone) and by Caraceni et al18 (fix-dose 
oxycodone plus moderate flexible-dose gabapentin [maxi-
mum 1800 mg]) in peripheral NeP. This combination is also 
Table 2 Combination therapy with pregabalin or gabapentin
Pregabalin/gabapentin 
combined with:
CDC rating of 
scientific evidence
RCTs testing the 
combination
Clinical practice experience concerning combinations
TCAs I + A Gilron et al10 and Holbech 
et al11
Combination well documented. Most with peripheral NeP. Useful 
combination for patients who do not tolerate either drug in larger 
doses, as well as sedative effect from TCA to improve sleep 
disturbance
SNRIs I/II + B/C Tesfaye et al12 and 
Tannenberg et al13
Combination reasonably well documented. Used by some of the 
experts with good effect and fewer side effects than with TCA 
SSRIs III + C None Insufficient evidence available. SSRIs not relevant in the treatment 
of NeP
Opioidsa I + B Gilron et al16, Hanna et al17 
and Caraceni et al18
Good evidence to support combination therapy. Frequently used 
in daily clinical practice
Other antiepilepticsb (Na+ 
channel blockers)
C None Insufficient evidence available. Combination could work in theory 
due to different mechanisms of action. Limited clinical experience
Cutaneous patches I + A/C Casale et al,19 Meier et al20 
and Irving et al21
Mixed evidence and results for localized NeP. Patches add-on to 
oral therapy are used by some experts with good effect
Others C None Insufficient evidence and clinical practice available
Notes: aIncluding synthetics. bMainly sodium channel blockers, but also multiple mode of action drugs (valproic acid and topiramate).
Abbreviations: CDC, Centers for Disease Control and Prevention; NeP, neuropathic pain; RCTs, randomized controlled trials; SNRIs, serotonin-noradrenaline reuptake 
inhibitors; SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants.
 
Jo
ur
na
l o
f P
ai
n 
Re
se
ar
ch
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
87
.1
74
 o
n 
27
-J
ul
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Journal of Pain Research  2017:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1471
Guidance on pharmacological combination treatment of NeP
frequently used in clinical practice (CDC rating I + B). Based 
on clinical experience, it was commented that the combina-
tion therapy results in increased effect, but with simultaneous 
increase in side effects relative to monotherapies. Although a 
class effect of opioids is often described, clinical experience 
shows a difference of effect between the opioids. Therefore, 
the opioid to select may depend on the single patient to 
treat and whether opioid therapy is already ongoing, that is, 
patients can react very differently on various opioids.
Insufficient scientific evidence was found by the Delphi 
panel for the combination of pregabalin/gabapentin and other 
antiepileptics (Table 2). In theory, the combination could be 
effective due to different mechanisms of action. However, 
neither sodium channel blockers such as lamotrigine nor 
multiple modes of action drugs such as topiramate have any 
certain role in the treatment of NeP.7 In general, this combi-
nation was seldom used by the experts.
No clear consensus was reached for the combination 
of pregabalin/gabapentin and cutaneous patches as studies 
are add-on and not combination studies (Table 2). Casale 
et al19 and Meier et al20 have studied lidocaine patches in 
clinical trials as add-on treatment to oral therapy, includ-
ing pregabalin/gabapentin, with good effect and hardly any 
side effects. Other trials, for example, Irving et al,21 added 
capsaicin patches to chronic pain medications, such as anti-
convulsants and found also a favorable response. Haanpää 
and  Hietaharju22 advocate for combining a locally acting 
preparation with a systemic drug for treatment of postherpetic 
neuralgia. The advisors gave mixed responses: good and 
insufficient evidence for localized NeP, which is the indica-
tion for patches. Overall, experience in clinical practice is 
that cutaneous patches can be combined with all types of 
oral therapy in patients who are suitable for local treatment.
Finally, the Delphi panel found insufficient scientific 
evidence for the combination of pregabalin/gabapentin 
and other pharmacological options like nonsteroidal anti-
inflammatory drugs and acetaminophen than those described 
above (Table 2).
Combination therapy with TCAs
Table 3 below presents the rating of the scientific evidence 
and clinical experience with combinations with TCAs. 
The combination therapy with pregabalin/gabapentin was 
described in the previous section and shown in Table 2.
The Delphi panel agreed that the evidence for the combi-
nation of TCAs and SNRIs was insufficient (CDC rating C) 
(Table 3). Although this combination is sometimes used in 
clinical practice, the overlapping side effect profile and the risk 
of serotonin syndrome makes this combination less useful.
For the combination of TCAs and SSRIs, moderate evi-
dence was found against its use and the Delphi panel would 
not recommend it (CDC rating D). This combination imposes 
a high risk of serotonin syndrome.
The majority of the Delphi panel found that there is good 
evidence for the combination of TCAs and opioids (CDC 
rating I + B) (Table 3). The scientific evidence is, however, 
divergent, dependent on the type of NeP. Mercadante et al23 
and Khoromi et al24 found no additional effect of the com-
bination for neuropathic cancer and lumbar pain, whereas 
in NeP of mixed causes, Gilron et al25 showed a favorable 
effect (flexible maximum tolerable dose [MTD] 100 mg 
morphine per day plus flexible MTD 100 mg nortriptyline 
Table 3 Combination therapy with TCAsa
TCAs combined with: CDC rating of 
scientific evidence
RCTs testing the 
combination
Clinical practice experience concerning combinations
SNRIs C None Insufficient evidence available. Overlap in mechanism of action makes 
the combination less useful in theory
SSRIs D None Moderate evidence against the use of the combination
Opioidsb I + B Mercadante et al,23 
Khoromi et al24 and 
Gilron et al25
Good evidence to support this combination. Frequently used in daily 
clinical practice
Other antiepilepticsc  
(Na+ channel blockers)
C None Insufficient evidence available. Combination could work in theory due to 
different mechanisms of action. Limited clinical experience
Cutaneous patches A/C None Insufficient evidence to support a recommendation for this combination 
therapy. Combination could work in theory
Others C None Insufficient evidence to support a recommendation for this
Notes: aFor the combination of TCAs and pregabalin/gabapentin see Table 2 above. bIncluding synthetics. cMainly sodium channel blockers, but also multiple mode of action 
drugs (valproic acid and topiramate).
Abbreviations: CDC, Centers for Disease Control and Prevention; RCTs, randomized controlled trials; SNRIs, serotonin-noradrenaline reuptake inhibitors; TCAs, tricyclic 
antidepressants.
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per day  compared with monotherapy with each drug). Mean 
MTD dose (mg ± SEM) of nortriptyline was 83.9±3.2 mg as 
monotherapy versus 60.2±4.6 mg in combination. Mean MTD 
dose of morphine was 65.4±4.3 mg as monotherapy versus 
60.2±4.6 mg in combination. The combination also led to 
fewer side effects than high-dose monotherapy. The combina-
tion of TCAs and opioids is frequently used by the experts.
For the combinations of TCAs and other antiepileptics, 
there is insufficient evidence to support a recommendation 
(CDC rating C) (Table 3). However, a combination of TCAs 
and a sodium channel blocker such as lamotrigine may be 
considered as a last resort for treatment of NeP.
Most experts (4 out of 6) in the panel found the evidence 
to be insufficient for the combination of TCAs and cutaneous 
patches; whereas others found it good (CDC rating A/C) even 
though no evidence from RCTs could be found. TCAs and 
patches with lidocaine/capsaicin have been used with favor-
able response and no increase in side effects by the experts.
The Delphi panel agreed that there is insufficient evidence 
to support a recommendation for the combination of TCAs and 
other drugs such as fluphenazine. The combination of TCAs 
and tramadol (CDC rating C) was an exception, as it has been 
used with good clinical experiences by few experts in the panel.
The Delphi panel underlines that caution is advised for 
use of TCA in the elderly because of anticholinergic side 
effects and cardiotoxicity.
Combination therapy with SNRIs
The ratings for the combinations of SNRI and other drugs 
apart from pregabalin/gabapentin or TCAs, are presented in 
Table 4 below.
Moderate evidence was found against the use of the com-
bination SNRI and SSRI, which is why it is not recommended 
(CDC rating D). Also, high risk of serotonin syndrome makes 
the combination inapplicable.
For all the other described combinations with SNRIs in 
Table 4, the panel agreed that there is insufficient evidence 
to support a recommendation for such a combination (CDC 
rating C). With respect to the combination of SNRIs and 
other antiepileptics, few practical experiences are available.
Combination therapy with SSRIs
The Delphi panel concluded that there was insufficient scien-
tific evidence to support a recommendation for any pharma-
cologic combination therapies with SSRIs. CDC rating was 
C for all possible combinations apart from combination with 
TCAs, which was rated D due to the high risk of serotonin 
syndrome with this combination. Basically, the panel agreed 
that SSRIs have no role in the treatment of NeP.
Combination therapy with opioids
The best evidence for the use of opioids in combination 
therapy is with pregabalin/gabapentin (Table 2) and TCAs 
(Table 3) (CDC rating I+B). There is insufficient evidence to 
support recommendations for combination of opioids with 
any of the other pharmacologic treatments – SNRIs, SSRIs, 
other antiepileptics (NA + channel blockers), cutaneous 
patches, and other pain pharmacological therapies (CDC rat-
ing C). Due to the regular use of opioids in pain management, 
there is some clinical experience with opioid combination 
therapy. This is mainly due to the fact that patients cannot be 
tapered off the opioid completely. Often patients are on opi-
oids because all other monotherapy options are without effect. 
Opioids are also combined with other pain pharmaceuticals 
like ketamine (10 mg × 3) in some patients with peripheral 
NeP and/or poor responders to first- and second-line drugs. 
In general, it would be beneficial, if the effect of opioids 
was not seen as a class effect, as clinical experience shows 
that there are meaningful differences between opioids within 
classes – dependent on the patient. For the multi-morbid frail 
old patients, who do not tolerate the usual first-line drugs 
for NeP, there are good clinical experiences with treatment 
with the dual-action agonist (combined opioid-agonist/
noradrenaline-re-uptake antagonist) drug tapentadol. Another 
Table 4 Combination therapy with SNRIsa
SNRIs combined with: CDC rating of  
scientific evidence
RCTs testing the 
combination
Clinical practice experience concerning combinations
SSRIs D None Moderate evidence against the use of the combination.
Opiodsb C None Insufficient evidence available. Combination could work in theory 
due to different mechanisms of action.
Other antiepilepticsc
(Na+ channel blockers)
C None Insufficient evidence available. Most experts have no experience with 
the combination. Combination could work in theory. 
Cutaneous patches C None Insufficient evidence available. Combination could work in theory. 
Others C None Insufficient evidence to support a recommendation for this.
Notes: aFor the combination of SNRIs and pregabalin/gabapentin see Table 2, and for the combination of SNRIs and TCAs see Table 3 above. bIncluding synthetics. cMainly 
sodium channel blockers, but also multiple mode of action drugs (valproic acid and topiramate). 
Abbreviations: CDC, Centers for Disease Control and Prevention; RCTs, randomized controlled trials; SNRIs, serotonin-noradrenaline reuptake inhibitors; TCAs, tricyclic 
antidepressants.
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possibility, when looking at interactions, side effects, poly-
pharmacy and compliance is buprenorphine patch combined 
with duloxetine, both in small doses.
When discussing opioids in general, the Delphi panel 
noticed that these drugs should be considered a last option 
in the treatment of chronic NeP of any cause, because of 
the risk of misuse, addiction and higher mortality related to 
these drugs.7
Combination therapy with other 
antiepileptics
The Delphi panel of experts concluded that there was no 
scientific evidence for combining any other antiepileptic with 
any other pharmacological therapies for NeP (CDC  rating C). 
Furthermore, there are limited experiences in clinical practice 
with these combinations although they may work in theory, 
as they would attack different mechanisms of action.
Combination therapy with cutaneous 
patches
Apart from the combination of cutaneous patches with pre-
gabalin/gabapentin, where there was some scientific evidence 
(CDC rating I + A/C, Table 2), the Delphi panel of experts 
concluded that there was insufficient evidence to support a 
recommendation (CDC rating C) for any other combination 
with cutaneous patches for the treatment of NeP.
However, for localized NeP, cutaneous patches should be 
considered because of low risk of side effects and combina-
tions with any oral treatment is possible.
Discussion
The present Delphi panel and process has investigated the use 
of combination therapy in the treatment and management of 
NeP based on the available scientific evidence as well as the 
existing clinical practice experience. Evidence is sparse and 
almost exclusively within peripheral NeP conditions. As a 
consequence of the limited evidence within central NeP, the 
drugs (including drug combinations) that have proven to be 
efficient within peripheral NeP are often applied for central 
NeP conditions in daily clinical practice.
The combination of pregabalin/gabapentin and TCAs was 
the best documented and experts had good clinical experi-
ence with this combination in the management of NeP. The 
combination pregabalin/gabapentin and SNRI (with focus on 
duloxetine) was also reasonably well documented with good 
clinical experience and fewer side effects than high-dose 
monotherapy. There is also good evidence for the use of 
opioids in combination with pregabalin/gabapentin or TCAs. 
However, because of misuse and addiction issues, there are 
the general recommendations against opioids, which hamper 
the use of these drugs.
The Delphi panel also concluded that cutaneous patches 
can be combined with most oral therapies in patients who 
are suitable for local treatment.
SSRIs, on the other hand, have no role in the treatment 
of NeP, neither in monotherapy nor in combination therapy.
The clinical experience from the Delphi panel shows that 
many combinations are useful and the idea of combining 
drugs with different mechanisms of action may be a feasible 
way of providing better pain relief for the individual patient.
The importance of dose adjustments is emphasized 
due to the overlap of side effects and the fact that NeP 
conditions are often dynamic. Dose titration in combina-
tion therapy has been a topic of discussion. The clinical 
experience is almost exclusively on add-on or sequential 
therapy, that is, starting with, for example, a TCA and 
titrating to a dose that might be limited by either side 
effects or insufficient effect and then adding, for example, 
pregabalin/gabapentin in a slow titration. Another approach 
is simultaneous titration of the drugs to the MTD, leading 
to a more balanced dose ratio.
The limited scientific literature on combination therapy 
makes it difficult to make recommendations based on hard 
evidence, which is also why the Cochrane review on combina-
tion pharmacotherapy for the treatment of NeP in adults from 
2012 concluded: “no combination treatment has sufficient 
evidence to be recommended in NeP”, Chaparro et al.8
Overall, the level of evidence is low as it is primarily 
based on a low number of expert opinions and clinical 
experiences. However, we cover a broad spectrum of clinical 
practice and academia with differences in medical specialties 
and clinical settings. In spite of the lack of sufficient evidence, 
the Delphi panel reached a similar conclusion to that of a 
Lancet review in 2013: “Escalating efforts to develop novel 
analgesics that surpass the efficacy of current treatments 
have not yet been successful; therefore, combination therapy 
remains an important beneficial strategy”, Gilron et al.26
Conclusion
Despite the fact that combination therapy is widely used in 
clinical practice with generally good results, existing guide-
lines on pain management do not contain much information 
or recommendations on combining pharmacological pain 
therapies to improve pain management in NeP. This Del-
phi process revealed that there is some scientific evidence 
available supporting the combinations of pharmacological 
pain therapies. Further studies on combination therapy are 
needed – also including non-pharmacological therapies, but 
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the present Delphi process results add important information 
to the existing knowledge on combination of pharmacologi-
cal pain therapies in NeP to be used in clinical practice and 
maybe in future guidelines.
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